In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority. The integration of genetic and omics data, such as gene expression (transcriptomics), proteomics or gut microbiome profiles, enriched with molecular modeling and in silico druggability studies, facilitate the comprehension of these unknown mechanisms. Exploitation of these results is a key step for selectively identifying therapeutic targets, predicting potential side effects and developing appropriate clinical trials with a higher chance of success. Our team has the necessary tools and expertise to realize the entire process.
Our research team, unique in Italy, involves researchers with expertise in: development of statistical and bioinformatic methods, analysis of big genomic data and in general omic- layers, screening and analysis of pharmacological databases, understanding of biological mechanisms regulating the immune and cardiometabolic system.
We have a long-lasting expertise in the field, for which we are recognized at an international scale. Through the identification of the most suitable, powerful and innovative bioinformatic methods, we guarantee a significant reduction in costs and running time, while maintaining high quality.
We offer:
- Consultation for design and analysis of large scale genetic and omic studies
- Bioinformatic analyses for the identification of potential therapeutic targets through systematic assessment of public data and integration of client’s/partner’s private data
- Screening in-silico of new molecules for known drug targets
- Consultation for designing an optimal clinical trial.